TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32005465

Group type: EXPERIMENTAL
Intervention: Conventional group (manual PAR scoring using study models)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indirect digital group (automated PAR scoring using scanned study models)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Direct digital group (automated PAR scoring using intraoral scans)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intraoral scanning
Number of subjects: 67

Group type: COMPARATOR
Intervention: Impression-taking
Number of subjects: 67
Study: 34267156

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HTS) (2 mL/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 20% mannitol (4.6 mL/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both 7.5% HTS and 20% mannitol
Number of subjects: 51
Study: 33860721

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone/10 mg yohimbine combined
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 35348015

Group type: EXPERIMENTAL
Intervention: Infant formula with specific prebiotics and postbiotics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 100

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 100
Study: 34719711

Group type: EXPERIMENTAL
Intervention: Palliative care screening tool administered daily for 8 weeks
Number of subjects: 17
Study: 32506733

Group type: EXPERIMENTAL
Intervention: TN + MB/PDT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TN + MAL/PDT
Number of subjects: 20
Study: 33811649

Group type: EXPERIMENTAL
Intervention: Group counseling based on the solution-focused approach (SFA)
Number of subjects: 31
Study: 33248239

Group type: EXPERIMENTAL
Intervention: Antebrachial access
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Brachial access
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Diabetic patients overall
Number of subjects: 410

Group type: COMPARATOR
Intervention: Nondiabetic patients overall
Number of subjects: 410
Study: 33493652

Group type: EXPERIMENTAL
Intervention: Philosophy for children (P4C) intervention
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBI)
Number of subjects: 37
Study: 32036983

Group type: EXPERIMENTAL
Intervention: 0.1% Eucalyptus leaves (EL) supplementation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.2% Eucalyptus leaves (EL) supplementation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (0% Eucalyptus leaves)
Number of subjects: 180
Study: 33962675

Group type: EXPERIMENTAL
Intervention: Neurocognitive Empowerment for Addiction Treatment (NEAT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 80
Study: 33313729

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 32741505

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Treatment (I-CBT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 111
Study: 35579016

Group type: EXPERIMENTAL
Intervention: MBH + EPO
Number of subjects: 42

Group type: COMPARATOR
Intervention: MBH alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EPO usage
Number of subjects: 42
Study: 33475138

Group type: EXPERIMENTAL
Intervention: Sitagliptin + insulin (SITA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Insulin alone (CONT)
Number of subjects: 51
Study: 32227157

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (4 cycles of 5-minute inflations and 5-minute deflations to the thigh to 110 mm Hg above systolic blood pressure) in addition to standard care
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (in addition to standard care)
Number of subjects: 188
Study: 33383266

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 60
Study: 32428718

Group type: EXPERIMENTAL
Intervention: Sleep-promoting intervention with eye patches and earplugs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 34244327

Group type: EXPERIMENTAL
Intervention: Serious injuries reported by participants
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Common injuries reported
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Injury occurrence related to activities
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Estimated treatment cost per injury
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Serious injuries over time
Number of subjects: 662
Study: 33591329

Group type: EXPERIMENTAL
Intervention: Vaginal mesh hysteropexy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 0
Study: 35621217

Group type: EXPERIMENTAL
Intervention: Broad digital intervention
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Focused digital intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 600
Study: 33662047

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for >6 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: No exclusive breastfeeding
Number of subjects: 202
Study: 33026421

Group type: EXPERIMENTAL
Intervention: Older age (age ≥60 years)
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: Fair skin (vs olive, dark, or black skin)
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: Inability to tan (vs ability to tan deeply)
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: Previous excisions of keratinocyte cancers (ever had an excision vs never had an excision)
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: Current smoking (vs never smoking)
Number of subjects: 40438

Group type: EXPERIMENTAL
Intervention: High alcohol use (≥14 alcoholic drinks per week vs no alcoholic drinks per week)
Number of subjects: 40438
Study: 35218519

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 48
Study: 32279612

Group type: EXPERIMENTAL
Intervention: Harikrishna Periwound Skin Classification (HPSC) after two months of clinical attachment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Harikrishna Periwound Skin Classification (HPSC) at zero months (before attachment)
Number of subjects: 30
Study: 35607304

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (added to control group treatment)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control group (subarachnoid block or combined lumbar epidural anesthesia with bupivacaine or bupivacaine and fentanyl)
Number of subjects: 580
Study: 32506579

Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 32909826

Group type: EXPERIMENTAL
Intervention: Insertion‐preserved hamstring tendon autografts (IP‐HT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Free hamstring tendon autografts (FHT)
Number of subjects: 45
Study: 34014975

Group type: EXPERIMENTAL
Intervention: Self-medication practice
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Self-medication for morning sickness
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Self-medication for headache
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Self-medication for upper respiratory tract infections
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Reasons for self-medication
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Absence of health insurance
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: First trimester of pregnancy
Number of subjects: 250
Study: 32836055

Group type: EXPERIMENTAL
Intervention: Droplet digital PCR (ddPCR) for detecting BRAF V600E mutations
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Droplet digital PCR (ddPCR)
Number of subjects: 35
Study: 35565715

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia defined as levels ≥ 15 µmol/L
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Boys (mean homocysteine levels 14.1 µmol/L)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Serum levels of vitamin B12
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Serum levels of folate
Number of subjects: 206
Study: 34453097

Group type: EXPERIMENTAL
Intervention: Unfavourable adiposity (82 SNPs)
Number of subjects: 321472

Group type: EXPERIMENTAL
Intervention: Favourable adiposity (24 SNPs)
Number of subjects: 321472

Group type: EXPERIMENTAL
Intervention: Neutral adiposity (25 SNPs)
Number of subjects: 321472
Study: 35235092

Group type: EXPERIMENTAL
Intervention: CBD (300 mg; oral)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 32299734

Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam (0.1 mg fentanyl and 5 mg midazolam)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Pethidine and diazepam (25 mg pethidine and 5 mg diazepam)
Number of subjects: 170
Study: 616168805

Group type: EXPERIMENTAL
Intervention: Intermediate frequency ultrasound combined with opioid analgesic (morphine)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Opioid analgesic (morphine) alone
Number of subjects: 162
Study: 33629956

Group type: EXPERIMENTAL
Intervention: myAID (web-based decision aid)
Number of subjects: 11

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 11
Study: 32456672

Group type: EXPERIMENTAL
Intervention: Stakeholder interviews
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Literature review
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Stakeholder input
Number of subjects: 84
Study: 36196975

Group type: EXPERIMENTAL
Intervention: Telephone-only (n = 23)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Audio-visual (n = 20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 43
Study: 33580606

Group type: EXPERIMENTAL
Intervention: Laughter yoga
Number of subjects: 75
Study: 32407272

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg (Maxolon 10 mg, GlaxoSmithKline, Pakistan) administered after rifampicin treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rifampicin 600 mg once daily for 6 days
Number of subjects: 12
Study: 36156678

Group type: EXPERIMENTAL
Intervention: Baseline iron deficiency
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Baseline iron deficiency among participants without anemia
Number of subjects: 2141
Study: 34140203

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block and transversus thoracis plane block
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgical infiltration of local anesthetics
Number of subjects: 22
Study: 32789625

Group type: EXPERIMENTAL
Intervention: Awareness of PrEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Willingness to take PrEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived efficacy of daily HIV pill
Number of subjects: 0
Study: 35315344

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 77
Study: 34323977

Group type: EXPERIMENTAL
Intervention: M2-deficient single replication (M2SR) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34511295

Group type: EXPERIMENTAL
Intervention: Aerosol box
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intubation tent
Number of subjects: 28

Group type: COMPARATOR
Intervention: No device use
Number of subjects: 28
Study: 34527408

Group type: EXPERIMENTAL
Intervention: 1 μg/kg fentanyl (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone + 1 μg/kg fentanyl (group 3)
Number of subjects: 60
Study: 33008345

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR), starting dose 2 mg/day, maintenance dose 4-6 mg/day for 50 weeks
Number of subjects: 191
Study: 36347555

Group type: EXPERIMENTAL
Intervention: Retrograde filling (RF) method
Number of subjects: 56

Group type: COMPARATOR
Intervention: Spontaneous voiding (SV) method
Number of subjects: 56
Study: 35703355

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 527
Study: 34976049

Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 50
Study: 35797794

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 20
Study: 32989579

Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (LMWH) prophylaxis alone starting from day 1 to day 15 at a dose of 1 mg/kg/day (maximum 120 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both pre‐ and postoperative LMWH starting from 12 hours preoperatively and continuing from day 1 to day 15 at the same dose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (LMWH) prophylaxis alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both pre‐ and postoperative LMWH
Number of subjects: 100
Study: 33687052

Group type: EXPERIMENTAL
Intervention: PRP-supplemented lipofilling with mechanically isolated SVF
Number of subjects: 28

Group type: COMPARATOR
Intervention: PRP-supplemented lipofilling
Number of subjects: 28
Study: 33340279

Group type: EXPERIMENTAL
Intervention: PC945 (5 mg single inhalation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC945 (5 mg daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC945 (0.5-10 mg single inhalation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC945 (daily 2-hour inhalation for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC945
Number of subjects: 0
Study: 32019696

Group type: EXPERIMENTAL
Intervention: High humility physician
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Low humility physician (ineffective)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Low humility physician (family practice)
Number of subjects: 417
Study: 35805787

Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with IL-6 SNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with GG IL-6 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week swimming training (ST group) with HSPA1A genotypes
Number of subjects: 0
Study: 34191185

Group type: EXPERIMENTAL
Intervention: Recurrent need for paracentesis
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Bilirubin (per 10 µmol/l increase)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Non-use of non-selective beta-blockers (NSBBs)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Development of hepatic hydrothorax
Number of subjects: 942
Study: 32091953

Group type: EXPERIMENTAL
Intervention: Chronic deep brain stimulation (DBS) of the caudal zona incerta (cZi)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Unilateral stimulation at increasing amplitude levels
Number of subjects: 35

Group type: COMPARATOR
Intervention: Bilateral and unilateral treatments
Number of subjects: 35
Study: 35074399

Group type: EXPERIMENTAL
Intervention: RX: xylazine (0.2 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RXD1: xylazine (0.2 mg/kg) and doxapram (0.1 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RXD2: xylazine (0.2 mg/kg) and doxapram (0.2 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: RS: saline
Number of subjects: 6
Study: 33330899

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 302 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 604 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) 906 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33824973

Group type: EXPERIMENTAL
Intervention: Motivational interviewing by a trained nurse practitioner (3 visits of 15 minutes each over 3 months)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard consultation by a nurse practitioner (after 1 and 3 months)
Number of subjects: 136
Study: 32271041

Group type: EXPERIMENTAL
Intervention: Hierarchical linear models (HLM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear regression with two‐way cluster adjusted standard errors
Number of subjects: 0
Study: 36247104

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (2 ml) plus dexmedetomidine 1 μg/kg diluted in 1 ml saline 0.9% (0.5 ml in each tonsil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levobupivacaine 0.25% (2 ml + 0.5 ml saline 0.9% per tonsil)
Number of subjects: 90
Study: 33814447

Group type: EXPERIMENTAL
Intervention: rosiglitazone and rosiglitazone XR
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 360
Study: 616118121

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Subretinal fluid (SRF) present
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Intraretinal fluid (IRF) present
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Retinal thickness <120 microns
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Greater subretinal tissue complex thickness
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Greater CNV lesion area
Number of subjects: 1185
Study: 32985265

Group type: EXPERIMENTAL
Intervention: Intensive balance and gait training (10 weeks, 3 times/week)
Number of subjects: 100
Study: 32074365

Group type: EXPERIMENTAL
Intervention: Web-based intervention (PTSD Clinicians Exchange)
Number of subjects: 605
Study: 34524370

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (G1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Therapeutic and aerobic exercise program (G2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aerobic exercise program (G3)
Number of subjects: 36
Study: 36361237

Group type: EXPERIMENTAL
Intervention: Opioid-Free Anaesthesia (OFA) combined with a paravertebral block with 0.5% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Typical general anaesthesia with opioids (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Opioid-Free Anaesthesia (OFA)
Number of subjects: 50
Study: 33648866

Group type: EXPERIMENTAL
Intervention: Acute IPC (3 × 5 min at 220 mmHg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Repeated IPC (3 days x 3 × 5 min at 220 mmHg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: SHAM (3 × 5 min at 20 mmHg)
Number of subjects: 23
Study: 32943079

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study: 34911711

Group type: COMPARATOR
Intervention: Patient Training Intervention (PTI)
Number of subjects: 2334

Group type: COMPARATOR
Intervention: Professional Training Intervention (PFI)
Number of subjects: 2334

Group type: COMPARATOR
Intervention: Combined Intervention (CBI)
Number of subjects: 2334

Group type: COMPARATOR
Intervention: PTI and CBI (smoking cessation)
Number of subjects: 2334
Study: 32897809

Group type: EXPERIMENTAL
Intervention: Supportive mothers
Number of subjects: 297

Group type: COMPARATOR
Intervention: Unsupportive mothers
Number of subjects: 297
Study: 34309927

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) at the trapezius muscle
Number of subjects: 2198

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) at the tibialis muscle
Number of subjects: 2198

Group type: EXPERIMENTAL
Intervention: Conditioning pain modulation (CPM)
Number of subjects: 2198
Study: 33044703

Group type: EXPERIMENTAL
Intervention: Quality Assurance (QA) practices
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Quality Control (QC) practices
Number of subjects: 23
Study: 616541541

Group type: EXPERIMENTAL
Intervention: Extended monitoring with entropy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 74
Study: 35573842

Group type: EXPERIMENTAL
Intervention: Background infusion group (2 mL/h infusion, 10-min lockout time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No background infusion group (6-min lockout time)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Background infusion group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 33184076

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35684144

Group type: EXPERIMENTAL
Intervention: HMB-enriched oral nutritional supplement (1.5 g of calcium HMB per bottle, twice a day for 12 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: HMB-free oral nutritional supplement (similar composition devoid of HMB, twice a day for 12 weeks)
Number of subjects: 43
Study: 34404678

Group type: EXPERIMENTAL
Intervention: Two-handed external chest compression (ECC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-handed external chest compression (ECC)
Number of subjects: 0
Study: 32869577

Group type: EXPERIMENTAL
Intervention: Along-meridian trochar acupuncture therapy, 3 times a week for 3 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture therapy with filiform needles, 5 times a week for 3 weeks.
Number of subjects: 80
Study: 35048993

Group type: EXPERIMENTAL
Intervention: VEPE cup
Number of subjects: 48

Group type: COMPARATOR
Intervention: UHMWPE cup
Number of subjects: 48
Study: 33160719

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 or 0.1 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ondansetron (8 mg intravenously)
Number of subjects: 30
Study: 32887521

Group type: EXPERIMENTAL
Intervention: Three-week savoring positive intervention via Facebook
Number of subjects: 61

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 61